Your selection
NoneFilter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
October 25, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … study; the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
October 19, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including LEQEMBI; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
BIOGEN TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS NOVEMBER 8, 2023
October 11, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
September 29, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … the potential of Biogen’s commercial business and pipeline programs; Biogen’s strategy and plans; and potential … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Completes Acquisition of Reata Pharmaceuticals
September 26, 2023 - … (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS ® , Reata Pharmaceuticals’ lead … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … (omaveloxolone), as well as other clinical and preclinical pipeline programs. SKYCLARYS ® , Reata Pharmaceuticals’ lead …
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
September 25, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including LEQEMBI; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Appoints Jane Grogan as Head of Research
September 6, 2023 - … responsible for research, discovery and preclinical pipeline, including development for the company’s first … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … and plans and the potential of our commercial business and pipeline programs; capital allocation and investment …
Biogen to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 30, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 4, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … the potential of Biogen’s commercial business and pipeline programs, including ZURZUVAE; the anticipated … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen to Acquire Reata Pharmaceuticals
July 28, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
